Searched for
CIPLA UK
Ahead of Market: 10 things that will decide stock market action on FridayBSE Sensex and Nifty 50 extended gains for a second session, led by banking, metal and pharma stocks despite IT weakness. Analysts flagged ...- Ahead of Market: 10 things that will decide stock market action on ThursdayNifty 50 and BSE Sensex declined, snapping a three-day rally due to IT and FMCG losses. Rising India VIX signaled caution, though broader t...
- Mitsubishi UFJ Financial sells 2.10% shares in CiplaPrior to the sale, MUFG had 5.56 per cent shares in Cipla.
- Buy Cipla, target Rs 603 : HSBCBuy Cipla Ltd. at a price target of Rs 603. The US ramp up as well as benefits from cost control initiatives should drive earnings.
- HSBC maintains ‘buy’ rating on Cipla“Assuming 10-15% market share and price discount of 25-30%, gSeretide could be a USD25-35m annual sales opportunity for Cipla,” said HSBC.
- Cipla jumps 2% after UK arm sells stake in Chase PharmaCipla had picked a 14.6 per cent stake in Chase Pharma for $1.5 million via a syndicated venture in 2014.
- Cipla divests 16.7 per cent stake in Chase Pharma to AllerganChase was recently financed by a Series B consortium consisting of New Rhein Healthcare, Edmond de Rothschild Investment Partners and Cipla...
- Buy Cipla, target Rs 570: HSBCHSBC expects earnings led recovery largely in the second half of FY17.
- Cipla invests additional $ 3 million in US's Chase PharmaceuticalsDrug firm Cipla Ltd has made an additional investment of USD 3 million in US-based Chase Pharmaceuticals engaged in developing novel approa...
- Cipla drug launches hold promise for FY17, grows in prescription businessGenerics sales in the US, launch of inhalers in the UK and a ramp up from its acquisitions are key positive factors to look forward to.
- Cipla slips as rival Mylan launches generic Seretide in UK's $400-mn anti-asthma drug marketShares of Cipla fell nearly 3 per cent intraday after rivals Mylan launched first generic version of anti-asthma drug Seretide.
- Cipla to acquire Brazil's Duomed Produtos for Rs 2.6 croreThe deal has the approval of Brazilian health authority (ANVISA) and other regulatory authorities to import and distribute pharmaceutical p...
- Cipla forms joint venture in Morocco to enhance position in African marketCipla (EU) Ltd, UK, a wholly-owned subsidiary of Mumbai-based drug firm, has inked the JV agreement with the Moroccan entities.
- Cipla rallies over 1% on tie-up plans UK's S&D Pharma; top Sensex gainerCipla said this collaboration will enable it to focus on its core therapy areas, while S&D Pharma will be the key partner for generics.
- Cipla announces commercial tie-up with UK's S&D PharmaPharmaceutical firm Cipla today announced commercial collaboration with UK-based S&D Pharma in the Czech Republic and Slovakia.
- Cipla launches combination inhalers in Germany and Sweeden; stocks touch all time high, may trigger reratingThe maiden launch increases the possibility and visibility of subsequent launches of the company’s inhalers in other countries.
- Stop step-motherly treatment of pharma sector in India: CiplaCipla Chairman Yusuf Hamied expressed hope that the new government would also take strong action over the issue of monopolies in the health...
- Cipla rallies nearly 2%, hits 52-week high on UK expansion plansThe pharma major is expected to invest nearly Rs 1,030 crore over next few years for launch and development of new drugs as part of its glo...
- Cipla to invest upto 100 million pounds in UK as part of expansionThe company will provide high quality affordable medicines to British National Health Service (NHS).
- Cipla to pick 14.6% stake in Chase Pharmaceuticals for $1.5 mnCipla also said it will make an additional USD 4.5 million investment in Chase upon achievement of certain milestones.
Load More- Buy Cipla, target Rs 603 : HSBC
